top of page

Some PAH patients on sotatercept can stop taking prostacyclin analogues

In a small study of 34 pulmonary arterial hypertension (PAH) patients taking triple therapy plus sotatercept, some were able to stop taking selexipag or treprostinil. The study didn't have a set protocol but considered each patient's situation individually.


Those whose PAH worsened when their prostacyclin analogue doses decreased or stopped regained their health once the dose was restarted. Those who were able to stop their prostacyclin analogue did not have their PAH worsen over the study follow-up period, which lasted at least 14 months. There were no specific characteristics showing which patients would or would not be able to stop prostacyclin therapies, and the long-term effects of stopping them is still unknown, so much more research needs to be done.


Read the European Respiratory Journal article. The paper is still in press, but the link will redirect to the final published version once it is available.

Recent Posts

Prostacyclin analogues for CTEPH?

This systemic review summarized the data from six studies that examined whether prostacyclin analogues are safe and useful when used to...

 
 
 

Comments


PHA Canada

408 - 55 Water Street

Office 8928

Vancouver, BC, V6B 1A1

Email: info@phacanada.ca

Phone: 604-682-1036

Toll Free: 1-877-774-2226

  • Instagram
  • Facebook
  • X
  • LinkedIn
  • Youtube

Charitable Registration # 872050224RR0001

Copyright 2025 PHA CANADA, ALL RIGHTS RESERVED   |   Website created by Creativibe   |   Powered by raisin

bottom of page